Skip to main content

Advertisement

SpringerLink
Log in

Gene therapy for breast cancer. — review of clinical gene therapy trials for breast cancer and mdr1 gene therapy trial in cancer institute hospital

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes; (2) enhancement of immunological response; (3) transfer of suicide genes; (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDRl) gene therapy. Advanced breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) withMDRl-transduced hematopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, andin vivo enrichment ofMDRl-transduced cells with docetaxel treatment has been seen. Both patients are in complete remission and had no apparent adverse effects from theMDRl gene transfer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hortobagyi GN: Treatment of breast cancer.N Engl J Med 339:974–984, 1998.

    Article  PubMed  CAS  Google Scholar 

  2. http://www4.od.nih.gov/oba/rac/clinicaltrial.htm.

  3. http://www.wiley.co.uk/genetherapy/clinical/.

  4. Osborne C, Wilson P, Tripathy D: Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications.Oncologist 9:361–377, 2004.

    Article  PubMed  CAS  Google Scholar 

  5. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J: p53 mutations in breast cancer.Cancer Res 52:5291–5298, 1992.

    PubMed  CAS  Google Scholar 

  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 344:783–792, 2001.

    Article  PubMed  CAS  Google Scholar 

  7. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D,et al: E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.Clin Cancer Res 6:250–259, 2000.

    PubMed  CAS  Google Scholar 

  8. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL,et al: Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.J Clin Oncol 19:3422–3433, 2001.

    PubMed  CAS  Google Scholar 

  9. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL: Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.Clin Cancer Res 7:1237–1245, 2001.

    PubMed  CAS  Google Scholar 

  10. Arteaga CL, Holt JT: Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice.Cancer Res 56:1098–1103, 1996.

    PubMed  CAS  Google Scholar 

  11. Holt JT, Arteaga CB, Robertson D, Moses HL: Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA.Hum Gene Ther 7:1367–1380, 1996.

    Article  PubMed  CAS  Google Scholar 

  12. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS,et al: Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy.Mol Med 7:271–282, 2001.

    PubMed  CAS  Google Scholar 

  13. Fisher B, Brown A, Wolmark N, Fisher ER, Redmond C, Wickerham DL, Margolese R, Dimitrov N, Pilch Y, Glass A,et al: Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10.Cancer 66:220–227, 1990.

    Article  PubMed  CAS  Google Scholar 

  14. Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA: Designing HER2 vaccines.Semin Oncol 29:53–61, 2002.

    PubMed  CAS  Google Scholar 

  15. Sivanandham M, Kim E, Wallack M Immunology, serum markers, and immunotherapy of mammarytumors. In: W. Donegan and J. Spratt (eds.), Cancer of the Breast, 5th edition. St Louis: Sanders, 2002.

    Google Scholar 

  16. Stewart AK, Lassam NJ, Graham FL, Gauldie J, Addison CL, Bailey DJ, Dessureault S, Dube ID, Gallenger S, Krajden M,et al: A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma.Hum Gene Ther 8:1403–1414, 1997.

    Article  PubMed  CAS  Google Scholar 

  17. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y,et al: Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.Gene Ther 6:350–363, 1999.

    Article  PubMed  CAS  Google Scholar 

  18. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong HS, Kim JA,et al: Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.Hum Gene Ther 12:671–684, 2001.

    Article  PubMed  CAS  Google Scholar 

  19. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor.Hum Gene Ther 3:57–73, 1992.

  20. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, Shearer M, Beuzeboc P, Van Belle S, Uzielly B,et al: Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2.J Biomed Biotechnol 2003:194–201, 2003.

    Article  PubMed  Google Scholar 

  21. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR: Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.J Clin Oncol 17:2180–2189, 1999.

    PubMed  CAS  Google Scholar 

  22. Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J,et al: Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.Clin Cancer Res 11:1512–1520, 2005.

    Article  PubMed  CAS  Google Scholar 

  23. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.Cancer 73:2157–2167, 1994.

    Article  PubMed  CAS  Google Scholar 

  24. Peters WP, Dansey RD, Klein JL, Baynes RD: High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer.Oncologist 5:1–13, 2000.

    Article  PubMed  CAS  Google Scholar 

  25. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP,et al: High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.J Clin Oncol 20:743–750, 2002.

    Article  PubMed  CAS  Google Scholar 

  26. Sugimoto Y, Tsuruo T: DNA-mediated transfer and cloning of a human multidrug-resistant gene of adriamycin-resistant myelogenous leukemia K562.Cancer Res 47:2620–2625, 1987.

    PubMed  CAS  Google Scholar 

  27. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDRl.Science 257:99–103, 1992.

    Article  PubMed  CAS  Google Scholar 

  28. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z,et al: Results of MDRl vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.Proc Natl Acad Sci USA 93:15346–15351, 1996.

    Article  PubMed  CAS  Google Scholar 

  29. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A,et al: Phase I trial of retroviral-mediated transfer of the human MDRl gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.J Clin Oncol 16:165–172, 1998.

    PubMed  CAS  Google Scholar 

  30. Cowan KH, Moscow JA, Huang H, Zujewski JA, O’Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G,et al: Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDRl) in metastatic breast cancer patients.Clin Cancer Res 5:1619–1628, 1999.

    PubMed  CAS  Google Scholar 

  31. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S,et al: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.N Engl J Med 346:1185–1193, 2002.

    Article  PubMed  CAS  Google Scholar 

  32. McCormack MP, Rabbitts TH: Activation of the T-cell oncogene LM02 after gene therapy for X-linked severe combined immunodeficiency.N Engl J Med 350:913–922, 2004.

    Article  PubMed  CAS  Google Scholar 

  33. Dave UP, Jenkins NA, Copeland NG: Gene therapy insertional mutagenesis insights.Science 303:333, 2004.

    Article  PubMed  Google Scholar 

  34. Berns A: Good news for gene therapy.N Engl J Med 350:1679–1680, 2004.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, 135-8500, Tokyo, Japan

    Shunji Takahashi, Yoshinori Ito & Kiyohiko Hatake

  2. Department of Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Japan

    Yoshikazu Sugimoto

  3. Department of Chemotherapy, Kyoritsu University of Pharmacy, Japan

    Yoshikazu Sugimoto

Authors
  1. Shunji Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshinori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiyohiko Hatake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshikazu Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shunji Takahashi.

About this article

Cite this article

Takahashi, S., Ito, Y., Hatake, K. et al. Gene therapy for breast cancer. — review of clinical gene therapy trials for breast cancer and mdr1 gene therapy trial in cancer institute hospital. Breast Cancer 13, 8–15 (2006). https://doi.org/10.2325/jbcs.13.8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.2325/jbcs.13.8

Keywords

Search

Navigation